Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | HAT1 | O14929 | 2/20 | 0.32 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20738926 | 1.00 | IMPDH2 (0.36) | IMPDH2GLAMEN1KMT2ARIPK1 | |
| SCHEMBL31026915 | 1.00 | IMPDH2 (0.36) | IMPDH2GLAMEN1KMT2ARIPK1 | |
| SCHEMBL22309192 | 0.80 | GLA (0.40) | GLAMEN1KMT2ARIPK1NPC1 | |
| SCHEMBL22069913 | 0.80 | GLA (0.40) | GLAMEN1KMT2ARIPK1NPC1 | |
| SCHEMBL25469179 | 0.76 | RIPK1 (0.46) | RIPK1TSHR | |
| SCHEMBL26606649 | 0.76 | RIPK1 (0.46) | RIPK1TSHR | |
| SCHEMBL22069911 | 0.75 | RIPK1 (0.44) | GLARIPK1SMN1; SMN2KDM4EHAT1 | |
| SCHEMBL24361064 | 0.74 | RIPK1 (0.44) | RIPK1TSHR | |
| SCHEMBL22308451 | 0.74 | RIPK1 (0.44) | RIPK1TSHR | |
| SCHEMBL22345950 | 0.73 | RIPK1 (0.41) | GLARIPK1KDM4EHAT1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321523-A2 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3666788-A1 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | IMPDH2 4086/4885GLA 1027/4885MEN1 707/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | IMPDH2 4086/4885GLA 1027/4885MEN1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.